Chemotherapy and quality of life in NSCLC PS 2 patients.
Details
Serval ID
serval:BIB_8FB90BB5A251
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Chemotherapy and quality of life in NSCLC PS 2 patients.
Journal
Acta oncologica
Working group(s)
Norwegian Lung Cancer Study Group
ISSN
1651-226X (Electronic)
ISSN-L
0284-186X
Publication state
Published
Issued date
2009
Peer-reviewed
Oui
Volume
48
Number
7
Pages
1019-1025
Language
english
Notes
Publication types: Clinical Trial, Phase III ; Journal Article ; Multicenter Study
Publication Status: ppublish
Publication Status: ppublish
Abstract
Nearly 40% of patients with advanced NSCLC are in performance status (PS) 2. These patients have a shorter life expectancy than PS 0/1 patients and they are underrepresented in clinical trials. Data on how platinum-based combination chemotherapy affects Health Related Quality of Life (HRQOL) of patients with PS 2 are scarce and the treatment of this important group of patients is controversial.
A national multicenter phase III study on platinum based chemotherapy to 432 advanced NSCLC patients included 123 patients with PS 2. To explore the treatment impact on HRQOL, the development of HRQOL during the first nine weeks were compared between PS 2 and PS 0/1 patients. We used the EORTC QLQ-C30 and QLQ-LC13 questionnaires. Standardized area under the curve for all HRQOL items, and HRQOL responses classified as better, stable or worse, were compared between the groups.
Whereas the demographic data at baseline were well balanced between the groups, the PS 2 patients had significantly worse function and more severe symptoms than the PS 0/1 patients. In response to combination chemotherapy, the PS 2 patients had a more profound improvement of global QOL, cognitive function, fatigue, dyspnea, sleeping problems and appetite loss in comparison to the PS 0/1 group.
PS 2 NSCLC patients seem to achieve valuable HRQOL benefits from platinum-based combination therapy. Prospective clinical studies with predefined HRQOL outcomes in PS 2 patients are needed to confirm these findings.
A national multicenter phase III study on platinum based chemotherapy to 432 advanced NSCLC patients included 123 patients with PS 2. To explore the treatment impact on HRQOL, the development of HRQOL during the first nine weeks were compared between PS 2 and PS 0/1 patients. We used the EORTC QLQ-C30 and QLQ-LC13 questionnaires. Standardized area under the curve for all HRQOL items, and HRQOL responses classified as better, stable or worse, were compared between the groups.
Whereas the demographic data at baseline were well balanced between the groups, the PS 2 patients had significantly worse function and more severe symptoms than the PS 0/1 patients. In response to combination chemotherapy, the PS 2 patients had a more profound improvement of global QOL, cognitive function, fatigue, dyspnea, sleeping problems and appetite loss in comparison to the PS 0/1 group.
PS 2 NSCLC patients seem to achieve valuable HRQOL benefits from platinum-based combination therapy. Prospective clinical studies with predefined HRQOL outcomes in PS 2 patients are needed to confirm these findings.
Keywords
Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Area Under Curve, Carboplatin/administration & dosage, Carboplatin/adverse effects, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Non-Small-Cell Lung/pathology, Carcinoma, Non-Small-Cell Lung/psychology, Deoxycytidine/administration & dosage, Deoxycytidine/adverse effects, Deoxycytidine/analogs & derivatives, Female, Humans, Karnofsky Performance Status, Life Expectancy, Lung Neoplasms/drug therapy, Lung Neoplasms/pathology, Lung Neoplasms/psychology, Male, Middle Aged, Neoplasm Staging, Patient Compliance, Quality of Life, Surveys and Questionnaires, Treatment Outcome, Vinblastine/administration & dosage, Vinblastine/adverse effects, Vinblastine/analogs & derivatives, Vinorelbine, Gemcitabine
Pubmed
Web of science
Publisher's website
Create date
10/03/2023 12:43
Last modification date
28/04/2023 5:54